The roles of toll-like receptors in carcinogenesis and cancer immunotherapy

Chinese-German Journal of Clinical Oncology

Volumn 9, Issue 2, 2010, Pages 118-120

  He, Lei ^a   Zhang, Lin ^b   Li, Zhaofeng ^a   Zhang, Quan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer; Immunotherapy; Signaling; Toll like receptors

Indexed keywords

CYTOKINE; TOLL LIKE RECEPTOR;

CANCER IMMUNOTHERAPY; CARCINOGENESIS; DENDRITIC CELL; HUMAN; INFLAMMATION; LEUKOCYTE; PROTEIN EXPRESSION; REVIEW;

EID: 77953566914     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/s10330-010-0008-8     Document Type: Review

References (21)

1. Gay NJ, Keith FJ. Drosophila toll and IL-1 receptor. Nature, 1991, 351: 355-356
2. Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu Rev Biochem, 2007, 76: 141-165
3. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol, 1989, 54: 1-13
4. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol, 2004, 4: 499-511
5. Takeda K, Akira S. TLR signaling pathways. Semin Immunol, 2004, 16: 3-9
6. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res, 2007, 67: 4346-4352
7. Hassan F, Islam S, Tumurkhuu G, et al. Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer, 2006, 6: 281-289
8. Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen associated molecular patterns are growth and survival factors for human myeloma cells through toll-like receptors. Leukemia, 2006, 20: 1130-1137
9. Killeen SD, Wang JH, Andrews EJ, et al. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer, 2006, 95: 247-252.
10. Chang YJ, Wu MS, Lin JT, et al. Induction of cyclooxygenase-2 over-expression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. Mol Pharmacol, 2004, 66: 1465-1477
11. Wang JH, Manning BJ, Wu QD, et al. Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism. J Immunol, 2003, 170: 795-804
12. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res, 2006, 66: 3859-3868
13. Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFa to TRAIL-mediated tumor regression. Cancer Cell, 2004, 6: 297-305
14. Tillman DK Jr, Caroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis, 2007, 79: 241-248
15. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem, 2001, 276: 10229-10233
16. Ilvesaro JM, Merrell MA, Swain TM, et al. Toll-like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 2007, 67: 774-781
17. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia, 2007, 21: 53-60
18. Mellor A, Baban B, Chandler P, et al. CpG oligonucleotides induce splenic CD19+ DCs to acquire IDO-dependent T cell regulatory functions via IFN signaling. J Immunol, 2005, 175: 5601-5605
19. Wang HY, Wang RF. Regulatory T cells and cancer. CurropinImmunol, 2007, 19: 217-223
20. Sutmuller RP, den Brok MH, Kramer M, et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest, 2006, 116: 485-494
21. Deane JA, Bolland S. Nucleic acid-sensing TLRs as modifiers of autoimmunity. J Immunol, 2006, 177: 6573-6578.